Ocular Proteomics Testing In Chronic Atrophy

Running, not enrolling · Not applicable

Conditions studied: Age-Related (Dry) Macular Degeneration

In brief

Study to evaluate the safety of routine diagnostic anterior chamber paracentesis (ACP) for proteomic profiling in patients with geographic atrophy (GA)

Key facts

Study ID

NCT07298291

Run by

ClinOmicsAI

People needed

50

Starts

2025-11-30

Expected to finish

2026-12-30

Last updated by the study team

2026-05-01

Who can join

Age: 50 and older, up to 89. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female subjects aged between 50 and 89 years, inclusive
• For the GA cohort: Clinical diagnosis of GA secondary to AMD or dAMD in the study eye, confirmed by fundus autofluorescence imaging and spectral-domain optical coherence tomography (SD-OCT).
• For the control cohort: No clinical evidence of retinal disease in either eye.
• Best-corrected visual acuity (BCVA) of ≥20/200 in the study eye, as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) charts
• Ability and willingness to provide written informed consent before any study-specific procedures.

You may not qualify if…

• Presence of active ocular infection or inflammation in either eye at the time of screening.
• History of intraocular surgery in the study eye within the three months preceding enrollment.
• Intraocular pressure (IOP) greater than 21 mmHg in the study eye at screening
• Use of systemic anticoagulation therapy that cannot be safely discontinued prior to ACP.
• Pregnant or nursing women.
• Known hypersensitivity or contraindication to any of the medications or procedures used in the study.

Where it is running

• Erie Retina Research — Erie, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.